BGLAP and diabetes mellitus: Antiresorptive therapies are hypothesized to increase undercarboxylated osteocalcin and thereby decrease diabetes incidence, however, in a post-hoc analysis of three randomized controlled trials the antiresorptive therapy did not affect fasting plasma glucose, weight loss, or diabetes risk (13).